Clinicians across multiple specialties

Reported complications described in some GLP-1 drug claims have included: Severe or persistent gastrointestinal symptoms , such as ongoing nausea, vomiting, or abdominal pain Delayed stomach emptying (gastroparesis) , which has been described by some individuals as involving bloating, nausea, vomiting, or difficulty tolerating food Intestinal complications , including reduced bowel activity (ileus), which may involve abdominal discomfort, cramping, or vomiting Gallbladder-related conditions , such as gallstones or gallbladder inflammation Blood-clot-related conditions , including deep vein thrombosis or pulmonary embolism, described in some reports and legal filings Vision-related problems , including reports involving non-arteritic anterior ischemic optic neuropathy (NAION) discussed in connection with semaglutide in certain contexts Not everyone who takes a GLP-1 medication experiences these issues, and the relationship between GLP-1 drugs and reported complications continues to be evaluated in legal proceedings

Acute effects on postprandial GLP-1 secretion and blood glucose response occur within hours of a single dose
Topiramate is not licensed for weight management in the UK, and any combined use should only occur under specialist medical supervision with careful monitoring of side effects and nutritional status
Why does my pharmacys date say 30 days, but online it says 28
11.2%, P 0.05), diabetic patients had a lower proportion of adenocarcinoma (61.7% vs